DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Atacicept
Atacicept
BAFF-Neutralizing Interaction of Belimumab Related to Its Therapeutic Efficacy for Treating Systemic Lupus Erythematosus
BCMA-Targeted Immunotherapy for Multiple Myeloma Bo Yu1, Tianbo Jiang2 and Delong Liu2*
Targeting BAFF and APRIL in Systemic Lupus Erythemathosis a Comparison of Trials of Three BAFF/APRIL Inhibitors
An Update on the Current State of Management and Clinical Trials for Iga Nephropathy
The Future of B-Cell Activating Factor Antagonists in the Treatment of Systemic Lupus Erythematosus
BAFF Suppresses IL-15 Expression in B Cells
By Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia
NDA/BLA Multi-Disciplinary Review and Evaluation
Effects of Sex and Aging on the Immune Cell Landscape As Assessed by Single-Cell Transcriptomic Analysis
BCMA) As a Target for New Drug Development in Relapsed And/Or Refractory Multiple Myeloma
European Journal of Neurology Accepted (14:10:2019) Version
Merck Kgaa, Darmstadt, Germany, Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics 09.11.202
BAFF- and APRIL-Targeted Therapy in Systemic Autoimmune Diseases Shingo Nakayamada and Yoshiya Tanaka*
UC San Francisco Previously Published Works
Atacicept in Relapsed&Sol;Refractory Multiple Myeloma Or Active
Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non ^ Hodgkin’S Lymphoma Stephen M
Efficacy and Safety of Atacicept for Prevention of Flares in Patients with Moderate-To-Severe Systemic Lupus Erythematosus
Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives
Top View
Belimumab Treatment for Adults with Systemic Lupus Erythematosus: a Review of Clinical Effectiveness, Cost- Effectiveness, and Guidelines
Phase II Data on the Safety and Efficacy of Atacicept at the 2016 ACR/ARHP Annual Meeting
Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: a Systematic Review of Agents Under Clinical Development
Uncovering an Adipocyte's Perspective of Inflammation And
Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab
B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis—Role in Pathogenesis and Effect of Immunosuppressive Treatments
A Critical Role for the Nfkb Pathway in Multiple Myeloma
Activation in Autoimmunity Released by ADAM10 and Reflects B Cell
SLE Drug Pipeline: an Embarrassment of Riches
Profile of Atacicept and Its Potential in the Treatment of Systemic Lupus Erythematosus
Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non ^ Hodgkin's Lymphoma
Single Cell Transcriptomic Re-Analysis of Immune Cells in Bronchoalveolar Lavage Fluids
Statistical Analysis Plan
Identification of 38 Novel Loci for Systemic Lupus Erythematosus And
BAFF Inhibition Effectively Suppresses the Development of Anti-HLA.A2 Antibody in the Highly Sensitized Mouse Model
Systematic Review of Safety and Efficacy of Atacicept in Treating
Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus
B-Lymphocyte Stimulator/A Proliferation-Inducing Ligand Heterotrimers Are
News Release Pursuing Novel Pathways in Immunology: Merck
B Cell Depletion Therapies in Autoimmune Disease: Advances and Mechanistic Insights